Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of three KSHV vaccine platforms and chimeric MHV68-K-G for in vivo mouse infection study

Award Number: U01CA294881
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

Development of three KSHV vaccine platforms and chimeric MHV68-K-G for in vivo mouse infection study - Abstract Kaposi's sarcoma-associated herpesvirus (KSHV) is a prevalent virus that establishes a lifelong persistent infection in humans and is associated with Kaposi's sarcoma (KS) and primary effusion lymphomas (PELs). Despite the reduction in complications associated with HIV infection due to combination antiretroviral therapy, KS still occurs in individuals with well-controlled HIV infection, in older men without HIV infection (classic KS), in sub-Saharan Africa (endemic KS), and in transplant recipients (iatrogenic KS). Despite being a pressing human health problem, very little research has been conducted to date on potential vaccine development against KSHV infection and its associated diseases. This is primarily due to the lack of significant interest as well as the absence of an effective animal model that supports in vivo studies on KSHV infection. For this reason, recombinant Murine Herpesvirus 68 (MHV68) has been used as the murine counterpart of KSHV in a small, manageable mouse model. The goal of this U01 application is twofold: firstly, to test three different novel vaccine platforms against KSHV infection, and secondly, to develop chimeric MHV68 carrying the replacement of KSHV glycoprotein (MHV68-K-G) as a surrogate challenge virus for testing the efficacy of KSHV vaccines in an in vivo mouse model.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $972,133 )
2025	2025	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Cancer Biology Research	001	2	9/15/2025	NON-COMPETING CONTINUATION	$972,133
2025	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Cancer Biology Research	000	1	12/5/2024	NEW	$0
														Subtotal = $972,133

Issue Date FY: 2024 ( Subtotal = $989,903 )
2024	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Cancer Biology Research	000	1	9/19/2024	NEW	$989,903
														Subtotal = $989,903

Grand Total All Awards = $1,962,036

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of three KSHV vaccine platforms and chimeric MHV68-K-G for in vivo mouse infection study

Award Number: U01CA294881

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer